Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Generalized Myasthenia Gravis
COMBINATION_PRODUCT: ALXN1720|COMBINATION_PRODUCT: Placebo
Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26, Baseline, Week 26
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26, Baseline, Week 26|Percentage of Responders Based on Reduction of the MG-ADL Total Score at Week 26, Response is defined as reduction of the MG-ADL total score by \>= 3 points from baseline at Week 26., Baseline up to Week 26|Percentage of Responders based on Reduction of the QMG Total Score at Week 26, Response is defined as reduction of the QMG total score by \>= 5 points from baseline at Week 26, Baseline up to Week 26|Change From Baseline in Myasthenia Gravis Composite (MGC) Total Score at Week 26, Baseline, Week 26|Change from Baseline in the QMG total score at Week 4, Baseline, Week 4
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).